

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
30 June 2005 (30.06.2005)

PCT

(10) International Publication Number
WO 2005/058328 A1

(51) International Patent Classification⁷: **A61K 31/55**,
C07D 223/16, A61P 25/00, C07D 409/12

(DE). SAUER, Daryl, R. [US/US]; 23619 - 112th Street, Trevor, WI 53179 (US).

(21) International Application Number:
PCT/EP2004/014428

(74) Agent: **REITSTÖTTER, KINZEBACH & PARTNER (GBR)**; Ludwigsplatz 4, 67059 Ludwigshafen (DE).

(22) International Filing Date:
17 December 2004 (17.12.2004)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/740,092 18 December 2003 (18.12.2003) US
60/530,806 18 December 2003 (18.12.2003) US

(71) Applicant (for all designated States except US): **ABBOTT GMBH & CO. KG [DE/DE]**; Max-Planck-Ring 2, 65205 Wiesbaden (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BRAJE, Wilfried [DE/DE]**; Unter dem Hopfenberge 15, 31737 Rinteln (DE). **HAUPT, Andreas [DE/DE]**; Schaelzigweg 52, 68723 Schwetzingen (DE). **LUBISCH, Wilfried [DE/DE]**; Haeusserstrasse 15, 69115 Heidelberg (DE). **GRANDEL, Roland [DE/DE]**; Birkenweg 49, 69221 Dossenheim (DE). **DRESCHER, Karla [DE/DE]**; Unteres Bieth 10, 69221 Dossenheim (DE). **GENESTE, Hervé [FR/DE]**; Rehbachstrasse 42, 67141 Neuhofen (DE). **UNGER, Liliane [DE/DE]**; Wollstrasse 129, 67065 Ludwigshafen


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **TETRAHYDROBENZAZEPINES AND THEIR USE IN THE MODULATION OF THE DOPAMINE D3 RECEPTOR**



pharmaceutical composition that comprises at least one tetrahydrobenzazepine compound of the formula (I), the physically tolerated acid addition salt of (I), the N-oxide of compound of the formula (I) and/or the physically tolerated acid addition salts of the N-oxides of (I), and further to the use of a compound according to the present invention for treating disorders that respond beneficially to dopamine D₃ receptor antagonists or dopamine D₃ agonists. The compounds according to the invention are preferably useful for the treatment of disorders of the central nervous system such as schizophrenia and depression and for the treatment of renal function disorders.

(57) Abstract: The invention relates to tetrahydrobenzazepines of the general formula (I) in which the variables Ar, A, B, Y, R¹ and R² have the meanings indicated in claim 1, as well as the N-oxides of these compounds, the physiologically tolerated acid addition salts of these compounds and the physiologically tolerated acid addition salts of the N-oxides. The invention also relates to a

physically tolerated acid addition salt of (I), the N-oxide of compound of the formula (I) and/or the physically tolerated acid addition salts of the N-oxides of (I), and further to the use of a compound according to the present invention for treating disorders that respond beneficially to dopamine D₃ receptor antagonists or dopamine D₃ agonists. The compounds according to the invention are preferably useful for the treatment of disorders of the central nervous system such as schizophrenia and depression and for the treatment of renal function disorders.